RNA biotech Nutcracker Therapeutics unshells $167M for drugs built on biochips

ARCH Venture Partners led the Series C round of financing for Nutcracker Therapeutics, a company developing new RNA drugs. The company’s process for developing and manufacturing RNA therapies borrows from techniques used in the technology sector.